335 related articles for article (PubMed ID: 27015221)
41.
Orquevaux P; Masseau A; Le Guern V; Gayet V; Vauthier D; Guettrot-Imbert G; Huong DLT; Wechsler B; Morel N; Cacoub P; Pennaforte JL; Piette JC; Costedoat-Chalumeau N
J Rheumatol; 2017 May; 44(5):613-618. PubMed ID: 28089975
[TBL] [Abstract][Full Text] [Related]
42. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?
Gómez-Puerta JA; Martín H; Amigo MC; Aguirre MA; Camps MT; Cuadrado MJ; Hughes GRV; Khamashta MA
Medicine (Baltimore); 2005 Jul; 84(4):225-230. PubMed ID: 16010207
[TBL] [Abstract][Full Text] [Related]
43. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.
Danowski A; de Azevedo MN; de Souza Papi JA; Petri M
J Rheumatol; 2009 Jun; 36(6):1195-9. PubMed ID: 19447935
[TBL] [Abstract][Full Text] [Related]
44. The antiphospholipid syndrome in patients with systemic lupus erythematosus.
Pons-Estel GJ; Andreoli L; Scanzi F; Cervera R; Tincani A
J Autoimmun; 2017 Jan; 76():10-20. PubMed ID: 27776934
[TBL] [Abstract][Full Text] [Related]
45. Extended Antiphospholipid Antibodies Screening in Systemic Lupus Erythematosus Patients.
Dima A; Caraiola S; Jurcut C; Balanescu E; Balanescu P; Ramba D; Badea C; Pompilian V; Ionescu R; Baicus A; Baicus C; Dan GA
Rom J Intern Med; 2015; 53(4):321-8. PubMed ID: 26939208
[TBL] [Abstract][Full Text] [Related]
46. Long-term outcome of patients with antiphospholipid syndrome who undergo percutaneous coronary intervention.
Perl L; Netzer A; Rechavia E; Bental T; Assali A; Codner P; Mager A; Battler A; Kornowski R; Lev EI
Cardiology; 2012; 122(2):76-82. PubMed ID: 22722386
[TBL] [Abstract][Full Text] [Related]
47. Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on β2GPI-specific T cell response.
Conti F; Spinelli FR; Alessandri C; Pacelli M; Ceccarelli F; Marocchi E; Montali A; Capozzi A; Buttari B; Profumo E; Sorice M; Arca M; Valesini G; Riganò R
Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):661-8. PubMed ID: 24436371
[TBL] [Abstract][Full Text] [Related]
48. Transcranial Doppler findings in antiphospholipid syndrome.
Ricarte IF; Dutra LA; Barsottini OGP; Souza AWS; Andrade DCO; Mangueira C; Silva GS
Lupus; 2019 Apr; 28(4):483-491. PubMed ID: 30755144
[TBL] [Abstract][Full Text] [Related]
49. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus.
Ruiz-Irastorza G; Egurbide MV; Ugalde J; Aguirre C
Arch Intern Med; 2004 Jan; 164(1):77-82. PubMed ID: 14718326
[TBL] [Abstract][Full Text] [Related]
50. [Primary antiphospholipid syndrome evolving into systemic lupus erythematosus: a report of 3 new cases and a review of the literature].
Blanco Y; Ramos-Casals M; García-Carrasco M; Cervera R; Font J; Ingelmo M
Rev Clin Esp; 1999 Sep; 199(9):586-8. PubMed ID: 10568151
[TBL] [Abstract][Full Text] [Related]
51. [Anxiety-depressive disorders and stress factors in patients with systemic lupus erythematosus and antiphospholipid syndrome].
Borisova AB; Veltishchev DY; Lisitsyna TA; Reshetnyak TM; Seravina OF; Kovalevskaya OB; Cheldieva FA; Abramkin AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(3):65-71. PubMed ID: 35394722
[TBL] [Abstract][Full Text] [Related]
52. Long-term neurodevelopmental outcome of children born to prospectively followed pregnancies of women with systemic lupus erythematosus and/or antiphospholipid syndrome.
Nalli C; Iodice A; Andreoli L; Galli J; Lojacono A; Motta M; Fazzi E; Tincani A
Lupus; 2017 Apr; 26(5):552-558. PubMed ID: 28394231
[TBL] [Abstract][Full Text] [Related]
53. [Retinal vascular lesions in systemic lupus erythematosus and secondary antiphospholipid syndrome].
Ermakova NA; Alekberova ZS; Reshetniak TM; Kalashnikova LA; Kosheleva NM
Vestn Oftalmol; 2005; 121(5):31-6. PubMed ID: 16274063
[TBL] [Abstract][Full Text] [Related]
54. Assessing the cardiovascular risk in patients with systemic lupus erythematosus: QRISK and GAPSS scores head-to-head.
Barinotti A; Radin M; Cecchi I; Foddai SG; Arbrile M; Rubini E; Menegatti E; Roccatello D; Sciascia S
Int J Cardiol; 2022 Sep; 363():185-189. PubMed ID: 35714714
[TBL] [Abstract][Full Text] [Related]
55. Cognitive disorders and antiphospholipid antibodies.
Yelnik CM; Kozora E; Appenzeller S
Autoimmun Rev; 2016 Dec; 15(12):1193-1198. PubMed ID: 27639839
[TBL] [Abstract][Full Text] [Related]
56. Children born to SLE and APS mothers.
Nalli C; Iodice A; Andreoli L; Lojacono A; Motta M; Fazzi E; Tincani A
Lupus; 2014 Oct; 23(12):1246-8. PubMed ID: 25228716
[TBL] [Abstract][Full Text] [Related]
57. Risk factors for cardiovascular diseases in patients with systemic lupus erythematosus: an umbrella review.
Katayama Y; Yanai R; Itaya T; Nagamine Y; Tanigawa K; Miyawaki Y
Clin Rheumatol; 2023 Nov; 42(11):2931-2941. PubMed ID: 37142864
[TBL] [Abstract][Full Text] [Related]
58. Antiphospholipid antibody tests: spreading the net.
Bertolaccini ML; Gomez S; Pareja JF; Theodoridou A; Sanna G; Hughes GR; Khamashta MA
Ann Rheum Dis; 2005 Nov; 64(11):1639-43. PubMed ID: 15817655
[TBL] [Abstract][Full Text] [Related]
59. Association of mannose-binding lectin gene polymorphisms with antiphospholipid syndrome, cardiovascular disease and chronic damage in patients with systemic lupus erythematosus.
Font J; Ramos-Casals M; Brito-Zerón P; Nardi N; Ibañez A; Suarez B; Jiménez S; Tàssies D; García-Criado A; Ros E; Sentís J; Reverter JC; Lozano F
Rheumatology (Oxford); 2007 Jan; 46(1):76-80. PubMed ID: 16801331
[TBL] [Abstract][Full Text] [Related]
60. Sudden Sensorineural Hearing Loss in Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Clinical Review.
Riera JL; Del R Maliandi M; Musuruana JL; Cavallasca JA
Curr Rheumatol Rev; 2020; 16(2):84-91. PubMed ID: 31804161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
